Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule

BACKGROUND: Dual delayed-release dexlansoprazole is approved for use in adults as a 30 mg orally disintegrating tablet (ODT) or as 30 mg and 60 mg capsules. The pharmacokinetics, pharmacodynamics, and safety profile of two dexlansoprazole 30 mg ODTs were compared with one dexlansoprazole 60 mg capsu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kukulka, Michael, Nudurupati, Sai, Perez, Maria Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076775/
https://www.ncbi.nlm.nih.gov/pubmed/27803732
http://dx.doi.org/10.1177/1756283X16666800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076775/
https://www.ncbi.nlm.nih.gov/pubmed/27803732
http://dx.doi.org/10.1177/1756283X16666800

Ejemplares similares